Structural Heart · 2017 · 28 citations · 17 references
MedicineCardiologySurgeryCardiothoracic SurgeryClinical CardiologyInterventional CardiologyAortic DiseaseAortic StenosisAortic SurgeryCardiac Valve SurgeryTranscatheter Aortic Valve ReplacementTranscatheter Valve TherapyBicuspid Aortic Valve StenosisHigh-risk Surgical PatientsSuccess Rate AnalysisSurvival RatesTricuspid Stenosis
BackgroundThere is limited data about transcatheter aortic valve replacement (TAVR) from China, where there are significant differences in the patient population both clinically and anatomically. This study sought to assess the clinical profile and outcomes of TAVR using the Venus MedTech A-valve in China.MethodsFrom 2012 to 2015, 101 patients with Society of Thoracic Surgeon (STS) scores ≥4% or at prohibitive surgical risk were enrolled from four academic cardiovascular centers in China. Among 97 patients with native aortic stenosis (AS), there were 44 (45.4%) bicuspid aortic valve (BAV) and 53 (54.6%) tricuspid aortic valve (TAV) replacements.ResultsPatients were 75.4 ± 6.4 years old, and the median STS score was 5.5% (inter-quartile range, IQR, 3.8%–9.2%). The device success rate was 84.2% (85/101) and the 2-year cumulative survival rates was 90.1% overall. There was no significant difference between the BAV and TAV arms for device success (79.5% vs. 86.8%; p = 0.06), annulus rupture (0%), and other procedural complications. Periprocedural paravalvular regurgitation ≥ moderate (11.4% in BAV vs. 6.0% in TAV, p = 0.56), 30-day mean gradients (10.0 [IQR, 7.0–13.0] mmHg in BAV vs. 10.0 [IQR, 6.0–14.0] mmHg in TAV; p = 0.85), and 30-day mortality (6.8% vs. 3.8%; p = 0.50) were also similar in both groups. Significant cardiac function improvements were observed in both groups at 30-day and 180-day follow-up. At 2 years, the cumulative survival rates (90.9% in BAV vs. 88.6% in TAV, p = 0.72) showed no significant differences between the two groups.ConclusionsThe AS population in China presenting for TAVR has a high prevalence of BAV. The treatments with a Chinese TAVR device are favorable and similar to those in TAV.
17
Transcatheter versus Surgical Aortic-Valve Replacement in High-Risk Patients
Craig R. Smith, Martin B. Leon, Michael J. Mack et al. · New England Journal of Medicine · 2011 · 6.3K citations · Full text
Medicine, Cardiology, Surgery +13
Outcomes Following Transcatheter Aortic Valve Replacement in the United States
Michael J. Mack, James M. Brennan, Ralph G. Brindis et al. · JAMA · 2013 · 472 citations
Medicine, Cardiology, Surgery +13
Jan‐Malte Sinning, Christoph Hammerstingl, Mariuca Vasa‐Nicotera et al. · Journal of the American College of Cardiology · 2012 · 405 citations
Medicine, Cardiology, Surgery +16